Total Payments
$475.19
2024 Payments
$187.71
Companies
12
Transactions
28
Medicare Patients
1,045
Medicare Billing
$80,920
Payment Breakdown by Category
Food & Beverage$475.19 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $475.19 | 28 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $130.08 | 8 | $0 (2024) |
| Novo Nordisk Inc | $116.65 | 6 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $41.97 | 3 | $0 (2021) |
| Amgen Inc. | $31.13 | 2 | $0 (2024) |
| Mylan Specialty L.P. | $31.12 | 2 | $0 (2021) |
| Eisai Inc. | $28.09 | 1 | $0 (2024) |
| Kowa Pharmaceuticals America, Inc. | $19.36 | 1 | $0 (2021) |
| Allergan, Inc. | $18.49 | 1 | $0 (2021) |
| Dexcom, Inc. | $17.89 | 1 | $0 (2024) |
| Amarin Pharma Inc. | $14.38 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $187.71 | 9 | Novo Nordisk Inc ($75.00) |
| 2023 | $47.16 | 3 | ABBVIE INC. ($31.21) |
| 2022 | $27.00 | 1 | ABBVIE INC. ($27.00) |
| 2021 | $213.32 | 15 | AbbVie Inc. ($50.26) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $28.09 | General |
| Category: Neurology | ||||||
| 11/06/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Endocrinology | ||||||
| 10/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: Cardiology | ||||||
| 10/29/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $27.26 | General |
| 10/16/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Biological | ||||||
| 10/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Obesity | ||||||
| 06/05/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Inflammation | ||||||
| 04/24/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: Obesity | ||||||
| 06/29/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: NEUROSCIENCE | ||||||
| 04/19/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.98 | General |
| Category: NEUROSCIENCE | ||||||
| 03/14/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Obesity | ||||||
| 05/13/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/06/2021 | Mylan Specialty L.P. | Yupelri (Drug) | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 07/29/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $19.36 | General |
| Category: Cardiovascular | ||||||
| 07/22/2021 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $12.21 | General |
| Category: Obesity | ||||||
| 07/20/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/08/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/04/2021 | Mylan Specialty L.P. | Yupelri (Drug), Perforomist | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 04/15/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: NEUROSCIENCE | ||||||
| 03/31/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: NEUROSCIENCE | ||||||
| 03/04/2021 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Cardiovascular | ||||||
| 02/02/2021 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 11 | 596 | 1,729 | $156,732 | $49,087 |
| 2020 | 10 | 449 | 581 | $114,855 | $31,833 |
Total Patients
1,045
Total Services
2,310
Medicare Billing
$80,920
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 15 | 1,020 | $38,760 | $16,576 | 42.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 181 | 219 | $57,159 | $16,110 | 28.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 112 | 134 | $23,718 | $7,050 | 29.7% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 38 | 38 | $4,750 | $2,524 | 53.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 36 | 36 | $14,436 | $2,455 | 17.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 63 | 72 | $7,560 | $2,115 | 28.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 32 | 81 | $5,265 | $687.28 | 13.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 38 | 38 | $988.00 | $646.38 | 65.4% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 33 | 37 | $1,776 | $482.98 | 27.2% |
| 69210 | Removal of impact ear wax, one ear | Office | 2021 | 11 | 11 | $1,331 | $294.12 | 22.1% |
| 81002 | Urinalysis, manual test | Office | 2021 | 37 | 43 | $989.00 | $146.47 | 14.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 152 | 219 | $57,159 | $15,225 | 26.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 107 | 137 | $24,249 | $6,560 | 27.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 34 | 34 | $13,634 | $3,402 | 24.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 33 | 33 | $8,613 | $3,260 | 37.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 39 | 48 | $5,040 | $1,440 | 28.6% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2020 | 15 | 15 | $1,875 | $915.00 | 48.8% |
| 87804 | Detection test for influenza virus | Office | 2020 | 12 | 24 | $1,344 | $393.90 | 29.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 21 | 30 | $1,950 | $281.89 | 14.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 16 | 16 | $416.00 | $268.16 | 64.5% |
| 81002 | Urinalysis, manual test | Office | 2020 | 20 | 25 | $575.00 | $86.58 | 15.1% |
About Leah Hurst, FNP-C
Leah Hurst, FNP-C is a Family healthcare provider based in Mathews, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/28/2020. The National Provider Identifier (NPI) number assigned to this provider is 1912538182.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Leah Hurst, FNP-C has received a total of $475.19 in payments from pharmaceutical and medical device companies, with $187.71 received in 2024. These payments were reported across 28 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($475.19).
As a Medicare-enrolled provider, Hurst has provided services to 1,045 Medicare beneficiaries, totaling 2,310 services with total Medicare billing of $80,920. Data is available for 2 years (2020–2021), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Mathews, VA
- Active Since 01/28/2020
- Last Updated 01/28/2020
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1912538182
Products in Payments
- VRAYLAR (Drug) $108.97
- Wegovy (Drug) $75.90
- XARELTO (Drug) $41.97
- Yupelri (Drug) $31.12
- Leqembi (Drug) $28.09
- VENCLEXTA (Drug) $27.00
- Livalo (Drug) $19.36
- Dexcom G6 Transmitter (Medical Supply) $17.89
- Otezla (Drug) $17.08
- Vascepa (Drug) $14.38
- Repatha (Biological) $14.05
- Veozah (Drug) $13.99
- Saxenda (Drug) $13.49
- UBRELVY (Drug) $12.60
- TRINTELLIX (Drug) $12.04
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.